Biological Deciphering of the “Kidney Governing Bones” Theory in Traditional Chinese Medicine

Zhu, Hanmin; Liu, Qi; Li, Wei; Huang, Shuming; Zhang, Bo; Wang, Yumei

doi:https://doi.org/10.1155/2022/1685052

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Data Availability Ethical Approval Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2022 | Article ID 1685052 | https://doi.org/10.1155/2022/1685052

Biological Deciphering of the “Kidney Governing Bones” Theory in Traditional Chinese Medicine

Hanmin Zhu,¹Qi Liu,²Wei Li,¹Shuming Huang,³Bo Zhang,³and Yumei Wang²

Academic Editor: Woon-Man Kung

Received03 Dec 2021

Revised22 Feb 2022

Accepted23 Feb 2022

Published29 Mar 2022

Abstract

The description of the “kidney” was entirely different from modern medicine. In traditional Chinese medicine (TCM), the kidney was a functional concept regulating water metabolism, which was closely related to the urinary system, reproductive system, nervous system, endocrine, skeleton, hearing, metabolism, immunity, etc. In particular, the kidney in TCM plays an important regulatory role in the processes of growth, development, prime, aging, and reproduction. Hence, “Kidney Governing Bone” (KGB) was a classical theory in TCM, which hypothesized that the function of the kidney was responsible for bone health. However, the related modern physiological mechanisms of this TCM theory are unclear. This present paper proposed a new understanding and explored the biological basis of the KGB theory. After searching through plenty of reported literature, we discovered that the functions of the kidney in TCM were closely associated with the hypothalamic-pituitary-gonadal (HPG) axis in modern science. The physiological mechanism of the KGB was regulated by sex hormones and their receptors. This review deciphered the connotation of the KGB theory in modern medicine and further verified the scientificity of the basic TCM theory.

1. Introduction

In traditional Chinese medicine (TCM), the kidney was a functional concept regulating water metabolism which was closely related to the urinary system, reproductive system, nervous system, endocrine, skeleton, hearing, metabolism, immunity, etc. It plays an important regulatory role in the processes of growth, development, prime, aging, and reproduction. Centuries ago, TCM owned abundant unique theories, of which the “Kidney Governing Bones” (KGB) theory was a vital one. This theory has been applied in the treatment of bone diseases over thousands of years. In the meantime, kidney reinforcing prescriptions have been confirmed with admirable effect by TCM practices in China [1–3]. However, the modern biological deciphering of the KGB theory remains unclear up to now.

Various hypotheses about mechanism of the KGB theory were proposed successfully. The main viewpoints were summarized as follows: (1) the kidney could affect the absorption of vitamin D; (2) the kidney could regulate the metabolism of trace elements such as calcium and phosphorus; (3) the kidney could regulate the secretion and metabolism of growth hormone; (4) the kidney could affect the OPG-RANKL-RANK signaling pathway; (5) the kidney could regulate the neuroendocrine-immune network (N-E-IN) [4, 5]. In brief, the kidney in TCM could regulate the processes of bone growth and metabolism through a variety of pathways. Sufficient understanding of the KGB theory could provide new insights for treating bone diseases in clinical trials. To our pleasure, plenty of physiology experimental results verified the scientificity of the abovementioned viewpoints.

Recently, studies have indicated that sex hormones play indispensable role in skeletal size, skeletal shape, and skeletal homeostasis during growth [6]. It was well known that the hypothalamic-pituitary-gonadal (HPG) axis carried out functions through sex hormones. Therefore, functions of the kidney in TCM were primarily related to functions of the HPG axis [7]. This article aimed to explore a modern scientific explanation of the KGB theory based on currently available studies on bone.

2. Definition of the Kidney in TCM

TCM described “kidneys” as a pair of organs located in the lumbar region, as the same in modern anatomy. However, the functions of the kidney in TCM were not identical to those in modern medicine. In TCM, the functions of the kidney include storage of essence, governance of water, bone protection, auditory regulation, reproduction promotion, and brain communication, as shown in Figure 1. In particular, according to an ancient book named Huang Di Nei Jing Su Wen, essence stored in the kidney was vital for human life. Therefore, the kidney in TCM is a functional concept, which is quite different from the definition in modern medicine.

3. The Correlation of the Function of the Kidney in TCM and the HPG Axis Biological Action in Modern Physiology

According to TCM, the kidney governs the reproductive function of humans. Both the maturity of sexual organs and the maintenance of sexual function are associated with the storage of essence in the kidney. According to an ancient TCM book titled Internal Classic Suwen, a woman’s kidney energy became vigorous at the age of 7 and Tiangui arrived at 14, after which the conception vessel and thoroughfare vessel became vigorous and the menstruation appeared, and the woman was able to conceive a baby. At the age of 49, as the conception vessel and thoroughfare vessel became deficient, the menstruation stopped, then the woman became physically feeble and was no longer able to conceive a baby. However, men’s kidneys become exuberant at the age of 8, then the kidney energy becomes prosperous at 16. After Tiangui arrived, the kidney essence became vigorous, and man was able to have an offspring. At the age of 64, as the kidney essence becomes deficient, the man becomes physically feeble and finally loses the ability to have a baby. Reproductive function depended on the conception vessel and thoroughfare vessel. Furthermore, the prosperity or decline of the conception vessel and thoroughfare vessel depended on Tiangui maturity and failure; however, Tiangui was derived from the essence of the kidney in TCM. Thus, a functional unit named “kidney-Tiangui-Conception vessel/thoroughfare vessel-Reproductive function” axis was built.

In modern physiology, the hypothalamus, a part of the hypothalamus-pituitary functional unit, is closely related to neuromodulation and humoral regulation. Peptidergic neurons, which are distributed in the pituitary gland’s arcuate nucleus of the hypothalamus, could secrete regulatory peptides. As a regulating peptide, gonadotropin-releasing hormone could regulate the release of gonadotropin by the pituitary gland through binding to a target membrane receptor. Furthermore, gonadotropin could regulate the secretion of sex hormones in gonads. This functional unit was widely known as the HPG axis. The HPG axis was involved in the process of sexual maturity. With the progression of age, the functions of the HPG axis descended consequently, and the reproductive function declined. Evidently, the reproductive function of the kidney in TCM was in fact the function of the HPG axis according to modern physiology.

4. Role of the Kidney/HPG Axis in the Maintenance of Bone Function and Bone Growth

4.1. Low Level of Sex Hormone Resulted in a High Incidence of Bone Diseases

Bone mass depends on the coordinated activities of bone-forming osteoblasts and bone-resorbing osteoclasts. Furthermore, the activity of osteoblasts and osteoclasts is controlled by a variety of hormones and cytokines [8]. Sex hormone was crucial to maintain bone mass; the lack of estrogen or testosterone resulted in a high incidence of bone diseases.

A large number of animal experimental studies indicated that the deficiency of sex hormones led to osteoporosis, which involved a decline of bone mass, changes of bone tissue microstructure, reduction of bone mineral density, and a loss of bone strength [9, 10]. These characteristics were observed in both male and female castrated animals [11]. Ovariectomized animals including rats [12], mice [13], and even sheep [14] have been used as disease models studying the generation and treatment of osteoporosis. In male animals, orchiectomy has been reported to reduce bone mineral density and bone intensity. Male animals that underwent orchiectomy were used as osteoporosis models [15–18].

In clinical practice, it was well known that sex hormones were the most important factor involved in the maintenance of bone mass. Deficiency of sex hormone was considered as a major cause of bone loss in osteoporosis patients [19–21]. An epidemiological study including 25,544 prostate cancer patients from 2004 to 2012 in New Zealand confirmed the association between androgen deprivation therapy (ADT) and fracture risk, demonstrating that ADT significantly increased the risk of bone diseases [22]. Another large cohort study investigated the influence of sexual hormone levels on bone diseases in 1,249 testicular cancer survivors and finally confirmed that testosterone deficiency was closely associated with bone diseases [23, 24]. In addition to some pathological factors, there are many drugs that can affect the hypothalamic-pituitary-gonadal (HPG) axis and then cause low bone mineral density, such as opiates and hormones [24–26].

4.2. Sex Hormones Acted on Bone as Growth Factors

Many factors are involved in the regulation of bone maturation, such as growth hormone, insulin-like growth factors, gonadal steroids, and other factors [27, 28]. Among these, sex hormones were currently considered as the most important factor associated with bone growth. Previous studies indicated that both testosterone and estradiol positively regulated the growth of the skeleton during the process of individual development, especially in childhood and adolescence. The levels were closely associated with areal bone mineral density and volumetric bone mineral density [29–31]. Reportedly, a decrease in estrogen level was observed in adolescent and young female athletes undergoing intense training regimens, and this decline was accompanied by a deficiency in peak bone mass [32]. Furthermore, lower bone mineral density was also observed in young men with hypogonadism in clinical studies [33]. Testosterone treatment has a significant improvement in lumbar spine and hip BMD in men with testosterone deficiency syndrome [34]. Studies showed that estrogen stimulated cancellous bone formation in both female and male animals. Estradiol increased the proportion of cancellous bone surfaces undergoing mineralization and mineral apposition rate in male mice [35], and estradiol increased areal bone mineral density, trabecular bone volume/tissue volume in vertebrae, and cortical thickness in the axial skeleton mediated by estrogen receptor-α in ovariectomized female mice [36, 37]. Furthermore, testosterone was also found to be essential for the formation of bone and maintenance of its structure; it increased the density of periosteal bone and trabecular bone via the androgen receptor in male mice [38]. Another study found that testosterone increased bone mineral density in the femur and spine and improved bone architecture (increased bone volume fraction, trabecular number, thickness, and connectivity density) in ovariectomized mice [39].

4.3. Involvement of Sex Hormones in Bone Metabolism

Bone metabolism was a complex process, the maintenance of bone structure and function was carried out by bone cells. In bone remodeling process, osteoclasts and osteoblasts play an important role [40]. Studies revealed that sex hormones were vital for bone metabolism [41]. Estrogen reduced the reabsorption of bone by inhibiting osteoclast activity [42] and enhanced the synthesis by increasing the number of osteoblasts by inhibiting apoptosis [43], decreasing oxidative stress [44], and reducing nuclear factor-κB (NF-κB) activity [45]. Hence, estrogen regulated bone metabolic process by interfering with remodeling and reabsorption [46, 47]. It was especially worth clarifying that estrogen was involved in the regulation of bone metabolism in both women and men [48]. However, the effects of testosterone on bone health were not well defined. Recently, studies showed that serum testosterone levels were associated with the risk of osteoporotic fracture in old men [49–51].

4.4. Involvement of Sex Hormones in Bone Metabolism Signaling Pathways

Plenty of cellular signaling pathways act as various networks by regulating or restricting each other, maintaining bone homeostasis [52]. Bone morphogenetic protein (BMP)/Smads, Wnt/β-catenin, and osteoprotegerin (OPG)/RANKL/RANK are considered as key signaling pathways that play important roles in bone metabolism [53, 54]. The BMP/Smads and Wnt/β-catenin signaling pathways are mainly responsible for bone formation, while the OPG/receptor activator of NF-κB ligand (RANKL)/RANK is mainly responsible for bone reabsorption [55]. Sex hormone affect bone metabolism by regulating the signaling pathways through a variety of mechanisms, such as regulating the expression of genes and affecting receptors [56, 57].

4.5. Involvement of Kidney’s Endocrine Function in Bone Metabolism

The kidney is not only an anatomical organ, but also a complex endocrine organ. Many components or hormones secreted by the kidney are involved in the regulation of bone metabolism. Erythropoietin (EPO) is a key regulator in bone remodeling produced in the kidney during adult life. Multipotent MSCs undergo EPO induced osteogenic transdifferentiation via the activation of EPO-R signaling pathways, leading to bone remodeling [58]. 1,25-dihydroxy-vitamin D₃, the active component of vitamin D, was produced in the kidney and mainly participated in bone formation by regulating calcium and phosphorus metabolism. While recent research studies suggested that vitamin D in bone appeared to have negative or positive roles depending on physiological and pathological circumstances, suggesting that vitamin D played pleiotropic role in bone metabolism [59]. Klotho expressed in the kidney coparticipated in the regulation of bone metabolism with FGF23 [60]. BMP was a powerful bone-inducing stimulator of bone formation and the cloud promoted the process of bone regeneration by promoting osteoblast precursors and osteoblast terminal differentiation from progenitor mesenchymal cells and bone progenitor cells. BMP-7 is an important member of the bone morphogenetic protein family that can be secreted by the kidney and promotes bone formation [61].

4.6. The Relationship of Neuroendocrine-Immune Network and the “KGB” Theory

The neuroendocrine-immune network (N-E-IN) suggested that there may be a common set of chemical information molecules and receptors among the neural, endocrine, and immune system. The intricate and complex interactions among these systems form a multidimensional network maintaining homeostasis and improving body function [62]. Estrogen affects the regulatory functions of the N-E-IN through a variety of ways [63]. The serotonin molecule is a classic neuroendocrine hormone. The serotonin worked on bone via two ways: (1) serotonin produced from peripheral acted as a hormone to inhibit bone formation, and (2) serotonin produced in the brain acted as a neurotransmitter exerting positive effect on bone mass by enhancing bone formation and limiting bone resorption [64]. Orexin is a critical neuropeptide that bidirectionally regulated skeletal homeostasis through positive and negative action. The functions depended on the distribution of orexin the blinked receptor. Orexin receptor 2 in the brain enhanced bone formation while orexin receptor 1 in the bone suppressed bone formation [65]. Osteocytes could secret neuropeptide Y under the control of the autonomic nervous system. Then, neuropeptide Y regulated bone marrow mesenchymal stem cells towards adipocytes rather than osteoblasts and finally led to bone loss and multiple bone diseases [66]. Substance P (SP) is an endogenous neuropeptide. SP ameliorated chronic inflammation by promoting the immune system and rejuvenating stem cells to promote the regeneration of osteoblasts [67]. Bone metabolism in the central nervous system is mainly regulated by the ventral hypothalamus. Galanin, a hypothalamic regulatory peptide, is an important regulatory factor [68]. However, the GABAergic neural circuit in the ventromedial hypothalamus can trigger bone loss without stressors [69]. To sum up, N-E-IN and “KGB” have a close relationship with each other. The mechanisms of bone homeostasis with “KBG” are shown in Table 1.

5. Kidney Deficiency Resulted in Bone Diseases

As bone is governed by the kidney in TCM, the sufficiency of the kidney essence is considered to be closely associated with the growth and function of bone. According to the ancient Chinese medical book named Huangdi Neijing, the kidney stores essence, essence generates marrow, marrow produces bone, and therefore, bone is governed by the kidney. With the progression of age, the kidney essence decreases gradually, and the individual becomes susceptible to bone diseases. Clinical studies reported that most patients with osteoporosis or lumbar intervertebral disc degeneration show symptoms of kidney deficiency. A high incidence rate of bone disease was observed in patients with impaired kidney function [70]. Some scholars investigated the association between kidney deficiency and bone mineral density using epidemiological methods, and indicated that bone mass loss and the incidence of osteoporosis in subjects with kidney deficiency were obviously higher than those in controls [71]. Furthermore, animal experiments confirmed that kidney deficiency affected the growth and condition of bones. It was reported that decreased collagen synthesis resulted in the degeneration of cervical vertebra, lumbar intervertebral disc, and articular cartilage of the knee in several kidney deficiency rat models [72].

6. Kidney Tonifying Prescriptions Showed Protection via Sex Hormones/Receptors

The kidney essence is especially vital for bones in TCM. Many bone diseases are caused by the insufficiency of kidney essence, and kidney tonifying prescriptions have ideal effects on some chronic diseases of the bone, as shown in Table 2. Osteoporosis is a metabolic bone disease that mainly occur in old people. Clinical research articles on the effects of kidney tonifying prescriptions on bone disease showed that many kidney tonifying prescriptions, such as Zuogui-wan [73], Yougui-wan [74, 75], and Liuweidihuang Pill [76, 77], [78–81] were effective in treating osteoporosis. The mechanisms by which kidney tonifying prescriptions treat bone diseases are complex. However, recently, some studies revealed that common pathways are increasing the effects of sex hormones/receptors or showing sex hormone-like action [82].

7. Summary

Summing up the above study, the functions of the kidney in TCM were in accordance with the functions of the HPG axis in modern physiology. The abovementioned content offered biological evidence of the KGB theory. In this paper, we clarified that the kidney in TCM is a functional concept, and the functions of the “Kidney-Tian gui-vital essence-reproductive function” axis in TCM and the HPG axis of modern science are closely similar. Sex hormone, the executors of HPG axis function, played a critical role in the maintenance of bone. Kidney deficiency or sex-hormone deficiency results in a high risk of bone diseases. Protective effects of kidney tonifying prescriptions in TCM were mediated by the sex hormone-like actions. In conclusion, we proposed a new explanation for the biological essence of the KGB theory in TCM, illustrating that the kidney mainlyregulats the actions of sex hormones or receptors that govern the bone. The biological deciphering of KGB theory was summarized as Figure 2.

Data Availability

The data supporting this review came from previously reported studies which have been cited.

Ethical Approval

This manuscript was a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

Hanmin Zhu and Qi Liu contributed equally to this work.

Acknowledgments

The authors would like to thank Dr. Hongdan Xu for his helpful discussion. The work was supported by Project of Qiqihar Academy of Medical Sciences (Grant Nos. 2021-ZDPY-011 and QMSI2021M-12). Fund of Heilongjiang Educational Department (Grant Nos. 2018-KYYWF-0080 and 2019-KYYWF-1258), National Natural Science Foundation of China (Grant Nos. 81873108 and 82003975), Hubei Educational Department Foundation (Grant No. B2020137), Project of Xiangyang Science and Technology of Hubei Province (Grant No. 2020ZD22), and Doctor Start-up Fund of Hubei Province (Grant No. 2059041).

References

W. Xiao-Qin, Z. Xin-Rong, and Z. Y. Clare, “From “kidneys govern bones” to chronic kidney disease, diabetes mellitus, and metabolic bone disorder: a crosstalk between traditional chinese medicine and modern science,” Evidence-based Complementary and Alternative Medicine, vol. 2016, Article ID 4370263, 8 pages, 2016.
View at: Publisher Site | Google Scholar
B. Yi-Ling, C. Yun-Hui, J. Cui et al., “Efficacy and safety of traditional Chinese medicine in the treatment of immune infertility based on the theory of “kidney deficiency and blood stasis”: a systematic review and meta-analysis,” Evidence-based Complementary and Alternative Medicine, vol. 2021, Article ID 9947348, 11 pages, 2021.
View at: Publisher Site | Google Scholar
L. M. Ming, L. N. Ning, G. Rui et al., “Uncovering the key mirnas and targets of the liuwei dihuang pill in diabetic nephropathy-related osteoporosis based on weighted gene co-expression network and network pharmacology analysis,” Endocrine, Metabolic & Immune Disorders Drug Targets, vol. 2021, Article ID 33588742, p. 16, 2021.
View at: Publisher Site | Google Scholar
D. Ju, M. Liu, H. Zhao, and W. Jun, “Mechanisms of “kidney governing bones” theory in traditional Chinese medicine,” Frontiers of Medicine, vol. 8, no. 3, pp. 389–393, 2014.
View at: Publisher Site | Google Scholar
W. Su-Juan, Y. Wei, R. Khalid et al., “Mechanism of treatment of kidney deficiency and osteoporosis is similar by traditional Chinese medicine,” Current Pharmaceutical Design, vol. 22, no. 3, pp. 12–20, 2016.
View at: Google Scholar
S. C. Manolagas, C. A. O’Brien, and M. Almeida, “The role of estrogen and androgen receptors in bone health and disease,” Nature Reviews Endocrinology, vol. 9, pp. 699–712, 2013.
View at: Publisher Site | Google Scholar
C. L. Meuwese and J. J. Carrero, “Chronic kidney disease and hypothalamic–pituitary Axis dysfunction: the chicken or the egg?” Archives of Medical Research, vol. 44, no. 8, pp. 591–600, 2013.
View at: Publisher Site | Google Scholar
P. Stefania, F. Milena, G. Gianluca, F. Salamanna, and V. Borsari, “The active role of osteoporosis in the interaction between osteoblasts and bone metastases,” Bone, vol. 79, pp. 176–182, 2015.
View at: Google Scholar
K. Ikeda, K. Horie-Inoue, and S. Inoue, “Functions of estrogen and estrogen receptor signaling on skeletal muscle,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 191, 2019.
View at: Publisher Site | Google Scholar
Y. Tomohiko, W. Jun, and H. S. Paula, “Gonadal Hormones and Bone,” Handbook of Experimental Pharmacology, vol. 262, pp. 65–91, 2019.
View at: Google Scholar
A. Maria, R. L. Michael, D. Vanessa et al., “Estrogens and androgens in skeletal physiology and pathophysiology,” Physiological Reviews, vol. 97, no. 1, pp. 135–187, 2017.
View at: Google Scholar
Y. Tiansong, W. Qingyong, Q. Yuanyuan et al., “Protective effect of rhaponticin on ovariectomy-induced osteoporosis in rats,” Journal of Biochemical and Molecular Toxicology, vol. 35, no. 9, Article ID e22837, 2021.
View at: Google Scholar
X. Qi, H. Liu, D. Bi et al., “Combined administration on You-Gui Yin and low-dose Raloxifene partially attenuates the bone loss in ovariectomized mice through the proliferation and osteogenic differentiation of bone marrow stromal cells,” Phytomedicine, vol. 53, 2018.
View at: Google Scholar
C. Healy, O. D. Kennedy, O. Brennan, S. M. Rackard, F. J. O’Brien, and T. C. Lee, “Structural adaptation and intracortical bone turnover in an ovine model of osteoporosis,” Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society, vol. 28, no. 2, pp. 248–251, 2010.
View at: Publisher Site | Google Scholar
R. S. Jun, R. Dal Sung, K. J. Yeol et al., “Changes in bone metabolism in young castrated male rats,” Yonsei Medical Journal, vol. 57, no. 6, 2016.
View at: Google Scholar
G. N. Amanda, G. G. Guidio, V. H. Meister et al., “Mandibular-related bone metabolism in orchiectomized rats treated with sex hormones,” Archives of Oral Biology, vol. 122, Article ID 105000, 2021.
View at: Google Scholar
C. Lulu, W. Guantong, W. Qinjue, Q. Liu, Q. Sun, and C. Lulu, “N-acetylcysteine prevents orchiectomy-induced osteoporosis by inhibiting oxidative stress and osteocyte senescence,” American Journal of Translational Research, vol. 11, no. 7, pp. 4337–4347, 2019.
View at: Google Scholar
W. Qian, M. J. Kessler, T. B. Kensler, and P. C. Dechow, “The mandibles of castrated male rhesus macaques (Macaca mulatta): the effects of orchidectomy on bone and teeth,” American Journal of Physical Anthropology, vol. 159, no. 1, pp. 31–51, 2016.
View at: Google Scholar
J. A. Carson and S. C. Manolagas, “Effects of sex steroids on bones and muscles: similarities, parallels, and putative interactions in health and disease,” Bone, vol. 80, pp. 67–78, 2015.
View at: Publisher Site | Google Scholar
C. Meier and M. E. Kraenzlin, “Gonadal hormones and their influence on skeletal health in men,” The Journal of Men’s Health & Gender, vol. 4, no. 2, pp. 181–191, 2006.
View at: Google Scholar
B. Frenkel, A. Hong, S. K. Baniwal et al., “Regulation of adult bone turnover by sex steroids,” Journal of Cellular Physiology, vol. 224, no. 2, pp. 305–310, 2010.
View at: Publisher Site | Google Scholar
A. Wang, Z. Obertová, C. Brown et al., “Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand,” BMC Cancer, vol. 15, no. 1, p. 837, 2015.
View at: Publisher Site | Google Scholar
M. Ondrusova, B. Spanikova, K. Sevcikova, and D. Ondrus, “Testosterone deficiency and bone metabolism damage in testicular cancer survivors,” American Journal of Men’s Health, vol. 12, no. 3, pp. 628–633, 2018.
View at: Publisher Site | Google Scholar
L. Wehbeh and A. S. Dobs, “Opioids and the hypothalamic-pituitary-gonadal (HPG) Axis,” Journal of Clinical Endocrinology & Metabolism, vol. 105, no. 9, pp. e3105–e3113, 2020.
View at: Publisher Site | Google Scholar
F. Gotthardt, C. Huber, C. Thierfelder et al., “Bone mineral density and its determinants in men with opioid dependence,” Journal of Bone and Mineral Metabolism, vol. 35, no. 1, pp. 99–107, 2017.
View at: Publisher Site | Google Scholar
L. B. Munshi, Y. Tsushima, K. Cheng, and M Brito, “Megestrol acetate-induced symptomatic hypogonadism in a male patient,” Case Reports in Endocrinology, vol. 2018, Article ID 7048610, 3 pages, 2018.
View at: Publisher Site | Google Scholar
H. Antonio, L. Antonio, M. Jesús, J. Gil, E. Ibarz, and G. Luis, “Male osteoporosis: a review,” World Journal of Orthopedics, vol. 3, no. 12, pp. 223–234, 2012.
View at: Google Scholar
B. Robert and O. Claes, “Translational studies provide insights for the etiology and treatment of cortical bone osteoporosis,” Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 32, no. 3, pp. 329–340, 2018.
View at: Google Scholar
S. Vandewalle, Y. Taes, T. Fiers et al., “Associations of sex steroids with bone maturation, bone mineral density, bone geometry, and body composition: a cross-sectional study in healthy male adolescents,” Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 7, pp. E1272–E1282, 2014.
View at: Publisher Site | Google Scholar
M. Nuri Ö, D. Hüseyin, B. R. Taner, and A. Baran, “Bone mineral density in adolescent girls with hypogonadotropic and hypergonadotropic hypogonadism,” Journal of Clinical Research in Pediatric Endocrinology, vol. 8, no. 2, pp. 163–169, 2016.
View at: Google Scholar
T. Pomerants, V. Tillmann, J. Jürimäe, and T. Jürimäe, “The influence of serum ghrelin, IGF axis and testosterone on bone mineral density in boys at different stages of sexual maturity,” Journal of Bone and Mineral Metabolism, vol. 25, no. 3, pp. 193–197, 2007.
View at: Publisher Site | Google Scholar
Y. Haq, “Endocrine disorders in adolescent and young female athletes: impact on growth, menstrual cycles,” Journal of Child and Adolescent Behavior, vol. 9, no. 4, 2021.
View at: Google Scholar
C. X. Li, S. T. Tang, and Q. Zhang, “Changes in bone mineral density and metabolic parameters after pulsatile gonadorelin treatment in young men with hypogonadotropic hypogonadism,” International Journal of Endocrinology, vol. 2015, Article ID 324524, 5 pages, 2015.
View at: Publisher Site | Google Scholar
J. Rodriguez-Tolrà, J. Torremadé, S. di Gregorio, L. del Rio, and E. Franco, “Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome,” Andrology, vol. 1, no. 4, pp. 570–575, 2013.
View at: Publisher Site | Google Scholar
E. M. Kathleen, J. P. Mark, L. G. Rachel, S. M. Colley, K. S. Korach, and J. H. Tobias, “Estrogen receptor-alpha dependency of estrogen’s stimulatory action on cancellous bone formation in male mice,” Endocrinology, vol. 144, no. 5, pp. 1994–1999, 2003.
View at: Google Scholar
“Erratum for “role of ERα in the effect of estradiol on cancellous and cortical femoral bone in growing female mice,” Endocrinology, vol. 158, no. 11, p. 4122, 2017.
View at: Google Scholar
K. L. Gustafsson, H. Farman, P. Henning et al., “The role of membrane ERα signaling in bone and other major estrogen responsive tissues,” Scientific Reports, vol. 6, Article ID 29473, 2016.
View at: Google Scholar
L. Vandenput, J. V. Swinnen, S. Boonen et al., “Role of the androgen receptor in skeletal homeostasis: the androgen‐resistant testicular feminized male mouse model,” Journal of Bone and Mineral Research, vol. 19, no. 9, pp. 1462–1470, 2004.
View at: Publisher Site | Google Scholar
T. G. Goetz, R. Mamillapalli, M. J. Devlin, A. E. Robbins, M. Majidi-Zolbin, and H. S. Taylor, “Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture,” American Journal of Physiology. Endocrinology and Metabolism, vol. 313, no. 5, p. E540, 2017.
View at: Publisher Site | Google Scholar
Y. Nishizawa, H. Ohta, M. Miura et al., “Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition),” Journal of Bone and Mineral Metabolism, vol. 31, no. 1, pp. 1–15, 2013.
View at: Publisher Site | Google Scholar
L. J. Robinson, B. B. Yaroslavskiy, R. D. Griswold et al., “Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-α with BCAR1 and Traf6,” Experimental Cell Research, vol. 315, no. 7, pp. 1287–1301, 2009.
View at: Publisher Site | Google Scholar
I. M. Ulrike, M. R. Matthew, H. Kelley et al., “Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women,” Bone, vol. 49, no. 2, pp. 202–207, 2011.
View at: Google Scholar
S. Kousteni, T. Bellido, L. I. Plotkin et al., “Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity,” Cell, vol. 104, no. 5, pp. 719–730, 2001.
View at: Google Scholar
A. Maria, H. Li, M. Marta et al., “Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids,” Journal of Biological Chemistry, vol. 282, no. 37, pp. 27285–27297, 2007.
View at: Google Scholar
C. Jia, W. Zhuo, T. Eric et al., “Inhibition of osteoblastic bone formation by nuclear factor-kappaB,” Nature Medicine, vol. 15, no. 6, pp. 682–689, 2009.
View at: Google Scholar
K. B. Emerton, B. Hu, A. A. Woo et al., “Osteocyte apoptosis and control of bone resorption following ovariectomy in mice,” Bone, vol. 46, no. 3, pp. 577–583, 2010.
View at: Google Scholar
M. Nisha, R. Hema, Z. Shunhui, R. B. Gerry, and R. B. Pilz, “Pro-survival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II,” Journal of Biological Chemistry, vol. 287, no. 2, pp. 978–988, 2012.
View at: Google Scholar
D. Vanderschueren, S. R. Pye, K. Venken et al., “Gonadal sex steroid status and bone health in middle-aged and elderly European men,” Osteoporosis International: A Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 21, no. 8, pp. 1331–1339, 2010.
View at: Publisher Site | Google Scholar
K. Narendra, U. Vimal, N. Amit, and K. V. S. Hari Kumar, “A prospective, observational study of osteoporosis in men,” Indian journal of endocrinology and metabolism, vol. 22, no. 1, pp. 62–66, 2018.
View at: Google Scholar
R. L. Machael, D. Lenore, D. Jolan, M. Bea, D. Marian, and E. Gielen, “Age-related bone loss and sarcopenia in men,” Maturitas, vol. 122, pp. 51–56, 2019.
View at: Google Scholar
S. Kazuyoshi, I. Kouji, K. Yoshifumi, and A. Mizokami, “Testosterone and bone health in men: a narrative review,” Journal of Clinical Medicine, vol. 10, no. 3, p. 530, 2021.
View at: Google Scholar
C. Guiqian, D. Chuxia, and L. Yi-Ping, “TGF-β and BMP signaling in osteoblast differentiation and bone formation,” International Journal of Biological Sciences, vol. 8, no. 2, pp. 272–288, 2012.
View at: Google Scholar
O. Zofia, K. Beata, M. Bogdan, K. Dariusz, and W.-P. Kinga, “Circadian Concentrations of Free Testosterone, Selected Markers of Bone Metabolism, Osteoprotegerin and its Ligand sRANKL in Obese Postmenopausal Women,” Postepy Higieny I Medycyny Doswiadczalnej (Online), vol. 65, pp. 658–667, 2011.
View at: Google Scholar
C. Sang, Y. Zhang, F. Chen et al., “Tumor necrosis factor alpha suppresses osteogenic differentiation of MSCs by inhibiting semaphorin 3B via Wnt/β-catenin signaling in estrogen-deficiency induced osteoporosis,” Bone, vol. 84, pp. 78–87, 2016.
View at: Publisher Site | Google Scholar
Y. Yuhei, M. Shingo, M. Masato et al., “BMP-induced Atoh8 attenuates osteoclastogenesis by suppressing Runx2 transcriptional activity and reducing the Rankl/Opg expression ratio in osteoblasts,” Bone research, vol. 8, no. 1, p. 32, 2020.
View at: Google Scholar
K. Yogesh, K. Isha, K. Kainat et al., “E3 ubiquitin ligase Fbw7 negatively regulates osteoblast differentiation by targeting Runx2 for degradation,” Journal of Biological Chemistry, vol. 290, no. 52, pp. 30975–30987, 2015.
View at: Google Scholar
F. Rivadeneira and O. Mäkitie, “Osteoporosis and bone mass disorders: from gene pathways to treatments,” Trends in Endocrinology and Metabolism: Trends in Endocrinology and Metabolism, vol. 27, no. 5, pp. 262–281, 2016.
View at: Publisher Site | Google Scholar
A. S. Tsiftsoglou, “Erythropoietin (EPO) as a key regulator of erythropoiesis, bone remodeling and endothelial transdifferentiation of multipotent mesenchymal stem cells (MSCs): implications in regenerative medicine,” Cells, vol. 10, no. 8, p. 2140, 2021.
View at: Publisher Site | Google Scholar
P. H. Anderson, “Vitamin D activity and metabolism in bone,” Current Osteoporosis Reports, vol. 15, no. 5, pp. 443–449, 2017.
View at: Publisher Site | Google Scholar
M. R. Haussler, G. K. Whitfield, I. Kaneko et al., “The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis,” Reviews in Endocrine and Metabolic Disorders, vol. 13, no. 1, pp. 57–69, 2012.
View at: Publisher Site | Google Scholar
N. Mathavan, M. Tägil, and H. Isaksson, “Do osteoporotic fractures constitute a greater recalcitrant challenge for skeletal regeneration? Investigating the efficacy of BMP-7 and zoledronate treatment of diaphyseal fractures in an open fracture osteoporotic rat model,” Osteoporosis International, vol. 28, no. 2, pp. 697–707, 2017.
View at: Publisher Site | Google Scholar
J. Cui, W. Song, Y. Jin et al., “Research progress on the mechanism of the acupuncture regulating neuro-endocrine-immune network system,” Veterinary Sciences, vol. 8, no. 8, p. 149, 2021.
View at: Publisher Site | Google Scholar
H. P Priyanka, R. S. Nair, and R. S Nair, “Neuroimmunomodulation by estrogen in health and disease,” AIMS Neuroscience, vol. 7, no. 4, pp. 401–417, 2020.
View at: Publisher Site | Google Scholar
P. Ducy and G. Karsenty, “The two faces of serotonin in bone biology,” Journal of Cell Biology, vol. 191, no. 1, pp. 7–13, 2010.
View at: Publisher Site | Google Scholar
W. Wei, T. Motoike, J. Y. Krzeszinski et al., “Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action,” Cell Metabolism, vol. 19, no. 6, pp. 927–940, 2014.
View at: Publisher Site | Google Scholar
Y. Zhang, C. Y. Chen, Y. W. Liu et al., “Neuronal induction of bone-fat imbalance through osteocyte neuropeptide Y,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany), vol. 8, no. 24, Article ID e2100808, 2021.
View at: Publisher Site | Google Scholar
J. Piao, J. S. Park, D. Y. Hwang, Y. Son, and H. S. Hong, “Substance P blocks ovariectomy-induced bone loss by modulating inflammation and potentiating stem cell function,” Aging, vol. 12, no. 20, pp. 20753–20777, 2020.
View at: Publisher Site | Google Scholar
A. Idelevich, K. Sato, K. Nagano, G. Rowe, F. Gori, and R. Baron, “Neuronal hypothalamic regulation of body metabolism and bone density is galanin dependent,” Journal of Clinical Investigation, vol. 128, no. 6, pp. 2626–2641, 2018.
View at: Publisher Site | Google Scholar
F. Yang, Y. Liu, S. Chen et al., “A GABAergic neural circuit in the ventromedial hypothalamus mediates chronic stress-induced bone loss,” Journal of Clinical Investigation, vol. 130, no. 12, pp. 6539–6554, 2020.
View at: Publisher Site | Google Scholar
S. Wang, W. Yue, K. Rahman et al., “Mechanism of treatment of kidney deficiency and osteoporosis is similar by traditional Chinese medicine,” Current Pharmaceutical Design, vol. 22, no. 3, pp. 312–320, 2015.
View at: Publisher Site | Google Scholar
R. Cong, G. Wei, L. Feng, and M. Xie, “Protective and therapeutic effects of Pilose antler against kidney deficiency-induced osteoporosis,” Cellular and Molecular Biology, vol. 65, no. 5, pp. 24–31, 2019.
View at: Google Scholar
Y. Chang-Feng, Z. Yong-Jian, N. Kai et al., “Experimental study on lumbar intervetebral disc degeneration model with kidney deficiency by ovariectomizing,” China Journal of Orthopaedics and Traumatology, vol. 26, no. 12, pp. 1015–1022, 2013.
View at: Google Scholar
N. Lai, Z. Zhang, B. Wang et al., “Regulatory effect of Traditional Chinese Medicinal Formula Zuo-Gui-Wan on the Th17/Treg paradigm in mice with bone loss induced by estrogen deficiency,” Journal of Ethnopharmacology, vol. 166, pp. 228–239, 2015.
View at: Publisher Site | Google Scholar
G. Fulong, J. Jiang, W. Sheng et al., “An experimental research into the potential therapeutic effects of Anti-Osteoporosis Decoction and Yougui Pill on ovariectomy-induced osteoporosis,” American Journal of Translational Research, vol. 11, no. 9, pp. 6032–6039, 2019.
View at: Google Scholar
P. Zhang, H. Xu, P. Wang et al., “Yougui pills exert osteoprotective effects on rabbit steroid-related osteonecrosis of the femoral head by activating β-catenin,” Biomedicine & Pharmacotherapy, vol. 120, Article ID 109520, 2019.
View at: Google Scholar
G. Rui, R. Shan, C. Menghui et al., “Corrigendum to “bioinformatics analysis reveals the altered gene expression of patients with postmenopausal osteoporosis using Liuweidihuang pills treatment,” BioMed Research International, vol. 2019, Article ID 6897187, 1 page, 2019.
View at: Publisher Site | Google Scholar
L. M. Ming, D. Rui, H. Zhen et al., “Therapeutic potential of Liuwei Dihuang Pill against KDM7a and Wnt/β-catenin signaling pathway in diabetic nephropathy-related osteoporosis,” Bioscience Reports, vol. 40, no. 9, 2020.
View at: Google Scholar
T. X. Yang, D. Z. Qin, S. D. Feng et al., “An UHPLC-MS/MS method for simultaneous determination of ten sex steroid hormones in ovariectomy-induced osteoporosis rat and its application in discovery of sex steroid hormones regulatory components of Xian-Ling-Gu-Bao capsule,” Journal of Pharmaceutical and Biomedical Analysis, vol. 195, Article ID 113888, 2021.
View at: Google Scholar
N. Zhu and J. Hou, “Exploring the mechanism of action Xianlingubao Prescription in the treatment of osteoporosis by network pharmacology,” Computational Biology and Chemistry, vol. 85, Article ID 107240, 2020.
View at: Publisher Site | Google Scholar
Q. Liu, A. Zhang, L. Wang et al., “High-throughput chinmedomics-based prediction of effective components and targets from herbal medicine AS1350,” Scientific Reports, vol. 6, no. 1, Article ID 38437, 2016.
View at: Publisher Site | Google Scholar
Z. Aihua, L. Qi, Z. Hongwei et al., “Phenotypic characterization of nanshi oral liquid alters metabolic signatures during disease prevention,” Scientific Reports, vol. 6, Article ID 19333, 2016.
View at: Google Scholar
Y. Li, S. S. Lü, G. Y. Tang et al., “Effect of Morinda officinalis capsule on osteoporosis in ovariectomized rats,” Chinese Journal of Natural Medicines, vol. 12, no. 3, pp. 204–212, 2014.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Hanmin Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1169

Downloads

730

Citations